Taxotere

Optimal Chemo-Hormonal Sequencing for mCRPC Maybe Taxotere – Zytiga – Jevtana – Xtandi 

Optimal Chemo-Hormonal Sequencing for mCRPC Maybe Taxotere – Zytiga – Jevtana – Xtandi 

Optimal Chemo-Hormonal Sequencing for metastatic castrate resistant prostate cancer (mCRPC) maybe Taxotere – Zytiga – Jevtana – Xtandi

Docetaxel (Taxotere) vs. Jevtana (Cabazitaxel)

Docetaxel (Taxotere) vs. Jevtana (Cabazitaxel)

The study concluded that significantly more men preferred Jevtana compared with Taxotere (43% vs 27%), whereas 30% of the men had no preference. The most common factors influencing preferences were fatigue, pain, hair loss, and patient-defined life quality.

 Adding Carboplatin To Chemotherapy May Improve Survival

 Adding Carboplatin To Chemotherapy May Improve Survival

According to research reported at the American Urological Association, 2020 Virtual Experience,” adding carboplatin to docetaxel chemotherapy for men with metastatic castration-resistant prostate cancer (mCRPC) and who failed either Xtandi or Zytiga may improve their survival.

Abiraterone or Docetaxel? 

Since the approvals for the early use of docetaxel chemotherapy (Taxotere) and the early use of abiraterone acetate (Zytiga) there is no clear evidence demonstrating which of these two agents should be used for men with hormone sensitive, newly diagnosed, aggressive prostate cancer. 

A Minimalist Real Time Empirical Look At Chemotherapy

Chemotherapy has a bad reputation because of its side effects.  This reputation has contributed to many men deciding not to use it in their treatment protocol.  Is this a mistake, we present a small amount of empirical evidence that this can be an error.